Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02602080 · ClinicalTrials.gov registry record
Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia
A clinical trial of Nausea and Emesis, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT02602080: Completed study of Nausea and Emesis, sponsored by Hospital for Special Surgery, New York.
NCT02602080 is a study of Nausea and Emesis that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 55 participants, below the 241-participant average among 17 other Nausea trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02602080, a study of Nausea and Emesis, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Nausea after surgery may negatively influence patient satisfaction, may delay discharge, and cause unexpected hospital admissions. The trend toward ambulatory surgery has increased the focus on postoperative nausea, but published evidence is not based on standardized criteria for assessment. Therefore, the results for postoperative nausea are very diverse, especially reports on nausea incidence after regional anesthesia, i.e. spinal anesthesia. When peripheral nerve blocks have been applied for postoperative pain control, they significantly reduce postoperative pain, opioid consumption and side effects; patients receiving general anesthesia (GA) and nerve blocks are thought likely to have less nausea than patients receiving GA alone. This study is a pilot study looking at the incidence and intensity of nausea after orthopedic surgery under nerve blocks in foot and ankle (FA) patients and under nerve blocks with either sedation or GA in total shoulder arthroplasty (TSA) patients. The results of this study will help power a future randomized controlled trial, comparing the incidence and intensity of nausea in FA patients receiving GA through laryngeal mask airway (LMA) versus spinal anesthesia.
Primary Outcome
Yes/no response to whether patient had nausea in the PACU 1 hour after admission. If yes, investigators will seek out intensity
Study Locations (1)
New York
- Hospital for Special Surgery, New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-04 |
What the finished NCT02602080 record still lists
NCT02602080 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 241-participant average among 17 other Nausea trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Nausea appearing as the primary indexed condition, and to 0 interventions.
NCT02602080 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02602080 about?
NCT02602080 is a clinical study titled "Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia". Nausea after surgery may negatively influence patient satisfaction, may delay discharge, and cause unexpected hospital admissions. The trend toward ambulatory surgery has increased the focus on postoperative nausea, but published evidence is not based on standardized criteria for assessment. Therefo...
What is the current status of trial NCT02602080?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2015-12. Estimated completion is 2016-04.
What conditions does trial NCT02602080 study?
This clinical trial studies the following conditions: Nausea, Emesis.
Who is sponsoring clinical trial NCT02602080?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02602080 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02602080's enrollment target sits among peer trials
55 14th of 17 higher than 4 of 17 other Nausea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nausea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Inhaled Isopropyl Alcohol for Treatment of Nausea
RECRUITING · Phase 2
-
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting
RECRUITING · NA
-
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
RECRUITING · Phase 2
-
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia